DanCann Pharma A/S with inspection by the Danish Medicine Agency during Q4-2022: expects to get EU-GMP approval before end-2022
COPENHAGEN, Denmark, November 8, 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announces that the Company expects to get the EU-GMP approval of the production facilities Biotech Pharm1 (“BP1”) in Q4 2022.Earlier this year DanCann Pharma applied for approval of the production facilities BP1. The Danish Medical Agency has informed the Company, that the inspection will take place in Q4 of 2022. The approval will be the most important milestone so far for DanCann Pharma and will open further market possibilities for